| Michael Gerges, | |
|
7917 John F Kennedy, North Bergen, NJ 07047 | |
| (201) 662-7575 | |
| Not Available |
| Full Name | Michael Gerges |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 7917 John F Kennedy, North Bergen, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053063768 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 28RI04138400 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Michael Gerges, 7801 5th Ave, North Bergen, NJ 07047-4961 Ph: (201) 662-7575 | Michael Gerges, 7917 John F Kennedy, North Bergen, NJ 07047 Ph: (201) 662-7575 |
News Archive
Preventing Alzheimer's from developing is a goal of Raphael Kopan, Ph.D., professor of molecular biology and pharmacology at the Washington University School of Medicine.
Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models.
Patients at risk of coronary disease who have reactive airways may breathe easier thanks to new data released today at the 15th Annual Scientific Session of the American Society of Nuclear Cardiology. A new study shows that regadenoson may be safely tolerated by patients with chronic lung disease, providing an alternative to adenosine, which is known to induce brochoconstriction in some patients.
An estimated quarter-million former service members would have been eligible for health coverage under the joint state-federal program but their states have opted not to participate in the expansion envisioned by the federal health law. Meanwhile in Iowa, hospitals were helpful in forging a compromise on the issue.
Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced today that the US Food and Drug Administration (FDA) has accepted its Extended Release Carbinoxamine Oral Suspension NDA for the treatment of allergies in kids two years and older. If approved, Tris Pharma's Extended Release Suspension will provide an alternative to the currently available immediate release formulations.
› Verified 9 days ago
Sau Yee Yip, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3147 Kennedy Blvd, North Bergen, NJ 07047 Phone: 201-865-7050 | |
Dr. Omar M Jaludi, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7527 Bergenline Ave, North Bergen, NJ 07047 Phone: 201-590-8776 | |
Mohammad Sohaib Iqbal, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9255 Kennedy Blvd, North Bergen, NJ 07047 Phone: 201-303-2771 | |
Mrs. Kari Lynne Stahl, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7101 Tonnelle Ave, North Bergen, NJ 07047 Phone: 201-520-1702 | |
Jane Lee, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7823 Bergenline Ave, North Bergen, NJ 07047 Phone: 201-869-1235 | |
Mr. Mohamed Fouad Hussein Sr., PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7527 Bergenline Ave, North Bergen, NJ 07047 Phone: 201-354-5700 |